Brief: Atara Biotherapeutics And Pierre Fabre Laboratories Announce Publication Of Phase 3 Allele Tab-Cel® Data In The Lancet Oncology

Atara Biotherapeutics

31/01/2024 23:32

Jan 31 (Reuters) - Atara Biotherapeutics Inc  ATRA.O :
    * ATARA BIOTHERAPEUTICS AND PIERRE FABRE LABORATORIES
ANNOUNCE
PUBLICATION OF PHASE 3 ALLELE TAB-CEL® DATA IN THE LANCET
ONCOLOGY
    * ATARA BIOTHERAPEUTICS INC - U.S. BLA ON TRACK FOR
SUBMISSION IN
Q2 2024 BASED ON STRONG CLINICAL FILE
    * ATARA BIOTHERAPEUTICS INC: 51.2% OBJECTIVE RESPONSE RATE
AND
23.0 MONTH MEDIAN DURATION OF RESPONSE IN RELAPSED OR REFRACTORY
EBV+ PTLD PATIENTS

Source text for Eikon:  ID:nBw7C1cTLa 
Further company coverage:  ATRA.O 

 ((Reuters.Briefs@thomsonreuters.com;))